Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | REPL |
---|---|---|
09:32 ET | 4960 | 11.79 |
09:34 ET | 8906 | 11.97 |
09:36 ET | 4300 | 11.96 |
09:38 ET | 3188 | 11.926 |
09:39 ET | 4684 | 11.685 |
09:41 ET | 9285 | 11.58 |
09:43 ET | 1804 | 11.61 |
09:45 ET | 2175 | 11.46 |
09:48 ET | 900 | 11.5 |
09:50 ET | 1500 | 11.52 |
09:52 ET | 1100 | 11.47 |
09:54 ET | 300 | 11.46 |
09:56 ET | 1200 | 11.52 |
09:57 ET | 11187 | 11.525 |
09:59 ET | 18704 | 11.51 |
10:01 ET | 4633 | 11.5 |
10:03 ET | 1517 | 11.505 |
10:06 ET | 2584 | 11.535 |
10:08 ET | 4573 | 11.5 |
10:10 ET | 5194 | 11.53 |
10:12 ET | 1148824 | 11.67 |
10:14 ET | 155748 | 11.68 |
10:15 ET | 1997 | 11.68 |
10:17 ET | 804 | 11.64 |
10:19 ET | 10963 | 11.515 |
10:21 ET | 6425 | 11.37 |
10:24 ET | 3795 | 11.2562 |
10:26 ET | 1218 | 11.35 |
10:28 ET | 4300 | 11.43 |
10:30 ET | 300 | 11.46 |
10:32 ET | 100 | 11.46 |
10:33 ET | 1459 | 11.43 |
10:35 ET | 200 | 11.39 |
10:37 ET | 2895 | 11.38 |
10:39 ET | 799 | 11.36 |
10:42 ET | 686 | 11.31 |
10:44 ET | 1306 | 11.43 |
10:46 ET | 200 | 11.475 |
10:48 ET | 400 | 11.49 |
10:50 ET | 1614 | 11.48 |
10:51 ET | 686 | 11.53 |
10:53 ET | 2260 | 11.57 |
10:55 ET | 550 | 11.5899 |
10:57 ET | 644 | 11.55 |
11:00 ET | 256 | 11.55 |
11:02 ET | 2000 | 11.59 |
11:06 ET | 700 | 11.63 |
11:08 ET | 600 | 11.65 |
11:09 ET | 1299 | 11.6 |
11:11 ET | 200 | 11.58 |
11:13 ET | 706 | 11.56 |
11:15 ET | 100 | 11.54 |
11:18 ET | 200 | 11.53 |
11:20 ET | 1566 | 11.57 |
11:22 ET | 920 | 11.57 |
11:24 ET | 555 | 11.5 |
11:26 ET | 1300 | 11.52 |
11:27 ET | 100 | 11.5 |
11:29 ET | 100 | 11.51 |
11:31 ET | 2375 | 11.59 |
11:33 ET | 312 | 11.595 |
11:36 ET | 200 | 11.6 |
11:38 ET | 1170 | 11.58 |
11:40 ET | 800 | 11.56 |
11:42 ET | 312 | 11.57 |
11:44 ET | 1455 | 11.6 |
11:45 ET | 200 | 11.645 |
11:47 ET | 617 | 11.64 |
11:49 ET | 100 | 11.64 |
11:51 ET | 300 | 11.63 |
11:54 ET | 2103 | 11.665 |
11:58 ET | 100 | 11.68 |
12:00 ET | 200 | 11.65 |
12:02 ET | 500 | 11.67 |
12:03 ET | 1700 | 11.73 |
12:05 ET | 1674 | 11.65 |
12:12 ET | 2300 | 11.65 |
12:14 ET | 1593 | 11.65 |
12:16 ET | 1874 | 11.69 |
12:18 ET | 1400 | 11.7 |
12:20 ET | 1593 | 11.7 |
12:21 ET | 2655 | 11.67 |
12:23 ET | 883 | 11.69 |
12:25 ET | 400 | 11.7 |
12:27 ET | 239 | 11.7 |
12:32 ET | 1531 | 11.71 |
12:34 ET | 2936 | 11.79 |
12:36 ET | 5160 | 11.83 |
12:38 ET | 1900 | 11.83 |
12:39 ET | 29250 | 11.91 |
12:41 ET | 800 | 11.94 |
12:43 ET | 6009 | 11.835 |
12:45 ET | 700 | 11.8 |
12:48 ET | 200 | 11.81 |
12:50 ET | 1200 | 11.88 |
12:52 ET | 8009 | 11.9 |
12:54 ET | 1579 | 11.87 |
12:56 ET | 3433 | 11.91 |
12:57 ET | 3837 | 12.07 |
12:59 ET | 16991 | 11.95 |
01:01 ET | 2626 | 11.95 |
01:03 ET | 700 | 11.92 |
01:06 ET | 314 | 11.905 |
01:08 ET | 589 | 11.91 |
01:10 ET | 2534 | 11.895 |
01:12 ET | 150 | 11.9 |
01:14 ET | 5395 | 11.875 |
01:15 ET | 510 | 11.885 |
01:17 ET | 308 | 11.87 |
01:19 ET | 3119 | 11.925 |
01:21 ET | 700 | 11.97 |
01:24 ET | 3128 | 11.93 |
01:26 ET | 1000 | 11.97 |
01:28 ET | 10109 | 11.9 |
01:30 ET | 650 | 11.9171 |
01:32 ET | 1599 | 11.95 |
01:33 ET | 1354 | 11.97 |
01:35 ET | 2020 | 11.96 |
01:37 ET | 4392 | 11.99 |
01:39 ET | 1975 | 11.99 |
01:42 ET | 5158 | 12.026 |
01:44 ET | 1855 | 12.02 |
01:46 ET | 898 | 12.06 |
01:48 ET | 1822 | 12.075 |
01:50 ET | 1135 | 12.105 |
01:51 ET | 1812 | 12.115 |
01:53 ET | 3619 | 12.13 |
01:55 ET | 944 | 12.205 |
01:57 ET | 8578 | 12.23 |
02:00 ET | 2508 | 12.26 |
02:02 ET | 6726 | 12.275 |
02:04 ET | 3092 | 12.3 |
02:06 ET | 3081 | 12.28 |
02:08 ET | 2561 | 12.26 |
02:09 ET | 4239 | 12.27 |
02:11 ET | 1314 | 12.31 |
02:13 ET | 1323 | 12.31 |
02:15 ET | 2490 | 12.28 |
02:18 ET | 2797 | 12.32 |
02:20 ET | 900 | 12.33 |
02:22 ET | 3039 | 12.355 |
02:24 ET | 2381 | 12.36 |
02:26 ET | 1703 | 12.32 |
02:27 ET | 1155 | 12.33 |
02:29 ET | 2051 | 12.26 |
02:31 ET | 1161 | 12.29 |
02:33 ET | 2281 | 12.31 |
02:36 ET | 829 | 12.3 |
02:38 ET | 1951 | 12.3 |
02:40 ET | 3518 | 12.31 |
02:42 ET | 2302 | 12.33 |
02:44 ET | 7966 | 12.375 |
02:45 ET | 2199 | 12.39 |
02:47 ET | 4492 | 12.42 |
02:49 ET | 634 | 12.43 |
02:51 ET | 19872 | 12.5299 |
02:54 ET | 3157 | 12.53 |
02:56 ET | 2078 | 12.54 |
02:58 ET | 2794 | 12.54 |
03:00 ET | 1704 | 12.53 |
03:02 ET | 2920 | 12.55 |
03:03 ET | 2759 | 12.55 |
03:05 ET | 600 | 12.51 |
03:07 ET | 4498 | 12.59 |
03:09 ET | 3279 | 12.63 |
03:12 ET | 5733 | 12.65 |
03:14 ET | 1651 | 12.61 |
03:16 ET | 2000 | 12.61 |
03:18 ET | 3308 | 12.61 |
03:20 ET | 2700 | 12.585 |
03:21 ET | 1000 | 12.639 |
03:23 ET | 6327 | 12.69 |
03:25 ET | 17463 | 12.78 |
03:27 ET | 3786 | 12.82 |
03:30 ET | 4579 | 12.84 |
03:32 ET | 17189 | 12.79 |
03:34 ET | 2260 | 12.76 |
03:36 ET | 62239 | 12.749 |
03:38 ET | 2468 | 12.79 |
03:39 ET | 7622 | 12.65 |
03:41 ET | 3318 | 12.62 |
03:43 ET | 4766 | 12.68 |
03:45 ET | 19640 | 12.52 |
03:48 ET | 9510 | 12.52 |
03:50 ET | 3618 | 12.48 |
03:52 ET | 17219 | 12.49 |
03:54 ET | 9109 | 12.375 |
03:56 ET | 21550 | 12.3 |
03:57 ET | 23958 | 12.285 |
03:59 ET | 259952 | 12.27 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Replimune Group Inc | 813.0M | -3.8x | --- |
Arrivent Biopharma Inc | 799.0M | -9.7x | --- |
Dianthus Therapeutics Inc | 818.4M | -5.1x | --- |
CARGO Therapeutics Inc | 838.7M | -5.2x | --- |
89Bio Inc | 779.5M | -3.7x | --- |
Nuvation Bio Inc | 770.0M | -1.0x | --- |
Replimune Group, Inc. a clinical-stage biotechnology company engaged in the development of a novel class of oncolytic immunotherapies. The Company’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. RP1 (vusolimogene oderparepvec) is its lead product candidate and is based on a proprietary strain of herpes simplex virus engineered and genetically armed with a fusogenic protein (GALV-GP R-) and GM-CSF intended to maximize tumor killing potency, the immunogenicity of tumor cell death, and the activation of a systemic anti-tumor immune response. It is also developing additional product candidates, RP2 and RP3, to enhance anti-tumor immune responses and are intended to address additional tumor types, including traditionally less immune responsive tumor types. RP2 additionally expresses an anti-CTLA-4 antibody-like molecule, as well as GALV-GP R- and GM-CSF.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $813.0M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 68.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.19 |
EPS | $-3.27 |
Book Value | $6.10 |
P/E Ratio | -3.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.